Alemtuzumab as a Therapy for Chronic Lung Allograft Dysfunction in Lung Transplant Recipients With Short Telomeres

Alemtuzumab, a monoclonal antibody targeting CD52 that causes lymphocyte apoptosis, is a form of advanced immunosuppression that is currently used as a therapy for refractory acute cellular rejection and chronic lung allograft dysfunction in lung transplant recipients (1–3). Side effects of alemtuzu...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Front Immunol
Huvudupphovsmän: Trindade, Anil J., Thaniyavarn, Tany, Townsend, Keri, Klasek, Robin, Tsveybel, Karen P., Kennedy, John C., Goldberg, Hilary J., El-Chemaly, Souheil
Materialtyp: Artigo
Språk:Inglês
Publicerad: Frontiers Media S.A. 2020
Ämnen:
Immunology
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7270280/
https://ncbi.nlm.nih.gov/pubmed/32547557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.01063
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk